Navigation Links
Dendreon Reports First Quarter 2009 Financial Results
Date:5/6/2009

SEATTLE, May 6 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today reported results for the first quarter ended March 31, 2009. Revenue for the first quarter of 2009 was $30,000 compared to $31,000 for the quarter ended March 31, 2008.

Dendreon's total operating expenses for the three months ended March 31, 2009 were $17.0 million compared to $19.2 million for the same period in 2008. The net loss for the quarter ended March 31, 2009 was $15.4 million, or $0.16 per share compared to a net loss for the same quarter of 2008 of $19.5 million, or $0.23 per share. Cash, cash equivalents, short-term, and long-term investments at March 31, 2009 totaled $91.2 million compared to $108.5 million at December 31, 2008.

Recent Events:

  • Reported final analysis of the IMPACT (IMmunotherapy for Prostate AdenoCarcinoma Treatment) Phase 3 trial for PROVENGE (sipuleucel-T) which demonstrated a statistically significant increase in overall survival. Data were presented at the American Urological Association (AUA) Annual Meeting. Based on these data, the Company intends to amend its Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) in the fourth quarter of this year.
  • Presented preclinical data at the AUA meeting announcing that D3263, a small molecule targeting TRPM8 (a transmembrane cation channel protein), reduced the size of the prostate in an animal model of benign prostatic hyperplasia (BPH) alone or in combination with finasteride.
  • Initiated a Phase 1 clinical trial of D3263 in patients with advanced cancer. The trial is an open-label, dose-escalation study evaluating the safety and pharmacokinetics of orally-administered D3263 targeting TRPM8 in patients with solid tumors that are refractory to standard therapies.

  • '/>"/>

SOURCE Dendreon Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Dendreon Announces Data Presentations and Webcast at AUA Annual Meeting
2. Dendreon Announces Data on PROVENGE Potency and Long-Term Immune Responses in Androgen-Dependent Prostate Cancer
3. Dendreon Reports Fourth Quarter and 2008 Year End Financial Results
4. Dendreon Announces Webcast Presentation at Eleventh Annual BIO CEO & Investor Conference
5. Dendreon Announces Webcast Presentation at 27th Annual J.P. Morgan Healthcare Conference
6. Dendreon Reports Third Quarter 2008 Financial Results
7. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
8. Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist
9. Dendreon Announces Webcast Presentation at UBS Global Life Sciences Conference
10. Dendreon Announces Webcast Presentation at Newsmakers in the Biotech Industry Conference
11. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... at the Institute for Molecular Medicine Finland (FIMM), ... developed a novel "man and machine" decision support ... aid was described in PLOS One ... based on computer vision algorithms similar to those ... of only the diagnostically most relevant areas. Tablet ...
(Date:8/21/2014)... COLD SPRING, N.Y. , Aug. 21, 2014 ... today the launch of their Nutraceutical "TELO-20 for ... first and only Telomere-lengthening supplement in the world ... the ends of every chromosome in the body. ... the world,s leading experts in Telomere Science and ...
(Date:8/21/2014)... Aug. 21, 2014  China Cord Blood Corporation (NYSE: ... to release financial results for the first quarter of ... market close in the US.  The ... ET on Friday, August 29, 2014 to discuss its ... Company,s recent developments, followed by a question and answer ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 ... has been recognized as one of the nation’s ... 5000 magazine for the 2nd consecutive year. Inc. ... 33rd annual Inc. 500|5000, an exclusive ranking of ... the most comprehensive look at the most important ...
Breaking Biology Technology:A novel 'man and machine' decision support system makes malaria diagnostics more effective 2Telomere Biosciences Announces: TELO-20 for Dogs, the World's First Telomere-Lengthening Supplement for Dogs, to Promote Healthy Aging and Longevity 2Telomere Biosciences Announces: TELO-20 for Dogs, the World's First Telomere-Lengthening Supplement for Dogs, to Promote Healthy Aging and Longevity 3China Cord Blood Corporation to Report First Quarter of Fiscal 2015 Financial Results 2SoundConnect Returns on Inc. 5000 List of Fastest Growing Companies 2SoundConnect Returns on Inc. 5000 List of Fastest Growing Companies 3
... With Trellis-8 Catheter From Bacchus Vascular, Reducing ... ... Calif., March 6 Bacchus Vascular Inc., a,leading provider of ... cardiologists for the,minimally invasive treatment of deep vein thrombosis (DVT) ...
... 5 /PRNewswire-FirstCall/ - Dragon Pharmaceutical Inc.,("Dragon" or ... DRP), a leading,international pharmaceutical company today announced ... for its core products 7ACA and,Clavulanic Acid ... to meet increasing,demand from its customers. Meanwhile, ...
... This release is available in German . ... individual organs, our cells themselves are made of tiny ... tasks. Such functional, nanostructured systems would also be useful ... components, or nanocapsules. However, it has not been possible ...
Cached Biology Technology:Major Medical Journal Reports Higher Success, Fewer Complications and Lower Cost Treating DVT With Trellis(R) Isolated Thrombolysis Compared With Catheter-Directed Thrombolysis 2Dragon announces new product launch; increase in annual production output capacity 2Dragon announces new product launch; increase in annual production output capacity 3Dragon announces new product launch; increase in annual production output capacity 4Cellular construction methods emulated 2
(Date:8/21/2014)... use a previously unknown process for harvesting energy and ... a Penn State University scientist has discovered. The discovery ... plant growth, harvesting energy from the Sun, and understanding ... and other lakes worldwide. A paper describing the discovery ... edition of the journal Science on 21 ...
(Date:8/21/2014)... linked to dandruff, eczema and other itchy, flaky maladies ... global reachesincluding Hawaiian coral reefs and the extreme environments ... review in the scientific journal PLOS Pathogens ... of the genus Malassezia in light of ... around the world. , University of Hawai,i at Mānoa ...
(Date:8/21/2014)... aimed at improving the food intake, health and quality ... is among three projects at the University of Waterloo ... Canadian Institutes of Health Research (CIHR). , Professor ... at Waterloo, and a Schlegel research chair in nutrition ... investigate why many Canadians living in long-term care homes ...
Breaking Biology News(10 mins):Hot-spring bacteria reveal ability to use far-red light for photosynthesis 2Hot-spring bacteria reveal ability to use far-red light for photosynthesis 3From dandruff to deep sea vents, an ecologically hyper-diverse fungus 2Grants will fund landmark aging research at Waterloo 2
... N.Y. and MUNICH, Nov. 7, 2012 Bausch + Lomb, the ... its option to purchase all outstanding and unowned shares of ... laser company. Technolas Perfect Vision was established in ... 20/10 PERFECT VISION AG to develop and sell advanced refractive ...
... drug, geldanamycin, is well known for attacking a protein ... laboratory-based study found it also degraded a different protein ... vessel growth is a key challenge in the battle ... human disease biology in the University of Leeds, Faculty ...
... (Philadelphia, PA) When a person has a heart attack, ... days or even weeks if deprived of oxygen for long ... growth of new blood vessels, in an attempt to regain ... remodeling is actually harmful, and the damaged heart is on ...
Cached Biology News:Bausch + Lomb to Acquire Technolas Perfect Vision GmbH 2Bausch + Lomb to Acquire Technolas Perfect Vision GmbH 3Breast cancer drug could halt other tumors 2Losing protein helps heart recover, say Temple scientists 2Losing protein helps heart recover, say Temple scientists 3
... you reduce the chance of error. Thats ... Developed using Beckman Coulters extensive experience in ... technology, the CEQ 8000 is a fully ... fills the capillary array with a patented ...
... Chemicon Detergent-OUT Kit is a simple high ... solutions. Removes detergents without significant dilution ... protein solution on the Detergent-OUT Spin column ... columns are suitable for removing detergent from ...
... The standard electrophoresis hood is ... documentation systems. Placed on the ... in place and provides a ... on the lab bench. This ...
... SDS Kit is a simple high performance ... Removes detergents without significant dilution of ... solution on the Detergent-OUT Spin column and ... columns are suitable for removing detergent from ...
Biology Products: